由粗榧科(Cephalotaxaceae)之台灣粗榧(Cephalotaxus wilsoniana Hayata)的心材、皮部、葉子,分離得到9 個已知的化合物: β-sitosterol (1),7-oxo-β-sitosterol (2),7β-hydroxy-β-sitosterol (3),4-hydroxy-3-methoxybenzaldeyde (4) , C-3-epi-wilsonine (5) , isoferulaldehyde (6),P-hydroxycinnamaldehyde (7),β-hydroxy-propioguaiacone (8),podocarpusflavone A (9),和一個新的diterpene化合物:12-hydroabieta-8,11,13-trien-3α-ol (10)。 將其中化合物5,9,及過去報告由本植物分離得之ginkgetin (11) 和taiwanhomoflavone A (12) , taiwanhomoflavone B (13) , taiwanhomoflavone C (14),進行對抗人類富含血小板血漿(platelet-rich plasma,PRP)以腎上腺素(epinephrine)誘發血小板凝集作用的抗凝集活性篩選的評估。 結果顯示,化合物11 和14 對人類富含血小板血漿(PRP)以腎上腺 素誘發之第二相凝集反應具有顯著地抑制作用且有濃度依賴機制, IC50 值分別約為293.6 µM 與259.3 µM。可知11 和14 乃經由抑制 thromboxane 之形成而抑制血小板之凝集。需更進ㄧ步地實驗才能確 立全部之作用機轉。11 和14 可發展成為抗血栓藥物。
A new diterpene, 12-hydroabieta-8,11,13-trien-3α-ol (10), together with nine known compounds, β-sitosterol (1), 7-oxo-β-sitosterol (2),7α-hydroxy-β-sitosterol (3), 4-hydroxy-3-methoxybenzaldeyde (4),C-3-epi-wilsonine (5), isoferulaldehyde (6), P-hydroxycinnamaldehyde(7), β-hydroxypropioguaiacone (8), podocarpusflavone A (9) have been isolated from the leaves, heartwood and bark of Cephalotaxus wilsoniana Hayata (Cephalotaxaceae). Compounds 5 and 9 and 11, 12, 13 and 14, previously isolated from this plant, were screened for antiplatelet effect on epinephrine-induced platelet aggregation in human platelet rich plasma (PRP). The result indicated that 11 and 14 significantly inhibited the secondary aggregation induced by epinephrine in human PRP and the inhibition was concentration-dependent manner. It indicated that their mechanism of action is chiefly due to the inhibition of thromboxane formation. It needs further experiments for determining the exact mechanism of action. Compounds 11 and 14 may be developed as antithrombotic drugs.